drugset / Trial / NCT04472650

Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults

NCT04472650

Phase 1 Completed 26 enrolled BeiGene
RandomizedCrossoverOpen-labelTreatment

Summary

The primary objective of the study was to investigate the relative bioavailability and pharmacokinetics (PK) of sitravatinib free base and malate salt capsule formulations following oral administration in healthy adults.

Timeline

Start
2020-07-23
Primary completion
2020-11-09
Completion
2020-11-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Sitravatinib Small molecule 100 mg Oral
Subject Sitravatinib Small molecule 120 mg Oral

Indications